JP2016519106A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519106A5
JP2016519106A5 JP2016507631A JP2016507631A JP2016519106A5 JP 2016519106 A5 JP2016519106 A5 JP 2016519106A5 JP 2016507631 A JP2016507631 A JP 2016507631A JP 2016507631 A JP2016507631 A JP 2016507631A JP 2016519106 A5 JP2016519106 A5 JP 2016519106A5
Authority
JP
Japan
Prior art keywords
compound
glycine
use according
bond
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016507631A
Other languages
English (en)
Japanese (ja)
Other versions
JP6420314B2 (ja
JP2016519106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033476 external-priority patent/WO2014169026A1/en
Publication of JP2016519106A publication Critical patent/JP2016519106A/ja
Publication of JP2016519106A5 publication Critical patent/JP2016519106A5/ja
Application granted granted Critical
Publication of JP6420314B2 publication Critical patent/JP6420314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016507631A 2013-04-10 2014-04-09 Metap2阻害剤及び肥満症の治療方法 Active JP6420314B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361810468P 2013-04-10 2013-04-10
US61/810,468 2013-04-10
US201461925918P 2014-01-10 2014-01-10
US61/925,918 2014-01-10
PCT/US2014/033476 WO2014169026A1 (en) 2013-04-10 2014-04-09 Metap2 inhibitors and methods of treating obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018192578A Division JP2019023219A (ja) 2013-04-10 2018-10-11 Metap2阻害剤及び肥満症の治療方法

Publications (3)

Publication Number Publication Date
JP2016519106A JP2016519106A (ja) 2016-06-30
JP2016519106A5 true JP2016519106A5 (https=) 2017-04-13
JP6420314B2 JP6420314B2 (ja) 2018-11-07

Family

ID=51686946

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016507631A Active JP6420314B2 (ja) 2013-04-10 2014-04-09 Metap2阻害剤及び肥満症の治療方法
JP2018192578A Pending JP2019023219A (ja) 2013-04-10 2018-10-11 Metap2阻害剤及び肥満症の治療方法
JP2021043481A Pending JP2021091738A (ja) 2013-04-10 2021-03-17 Metap2阻害剤及び肥満症の治療方法
JP2023061783A Active JP7681054B2 (ja) 2013-04-10 2023-04-05 Metap2阻害剤及び肥満症の治療方法
JP2025078682A Pending JP2025109807A (ja) 2013-04-10 2025-05-09 Metap2阻害剤及び肥満症の治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018192578A Pending JP2019023219A (ja) 2013-04-10 2018-10-11 Metap2阻害剤及び肥満症の治療方法
JP2021043481A Pending JP2021091738A (ja) 2013-04-10 2021-03-17 Metap2阻害剤及び肥満症の治療方法
JP2023061783A Active JP7681054B2 (ja) 2013-04-10 2023-04-05 Metap2阻害剤及び肥満症の治療方法
JP2025078682A Pending JP2025109807A (ja) 2013-04-10 2025-05-09 Metap2阻害剤及び肥満症の治療方法

Country Status (12)

Country Link
US (9) US9173956B2 (https=)
EP (2) EP3574922B1 (https=)
JP (5) JP6420314B2 (https=)
CN (2) CN105431426A (https=)
AU (1) AU2014250983B2 (https=)
BR (1) BR112015025892A2 (https=)
CA (1) CA2908993C (https=)
DK (2) DK3574922T3 (https=)
EA (1) EA033912B1 (https=)
ES (2) ES2749746T3 (https=)
MX (2) MX386958B (https=)
WO (1) WO2014169026A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150022A2 (en) * 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
CA2908993C (en) * 2013-04-10 2023-05-23 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity
CN106432255A (zh) * 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
ES2893749T3 (es) * 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3239447A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス,インコーポレイティド MetAP2阻害剤のバイオマーカーとその応用
CN112500314B (zh) * 2020-09-14 2022-05-13 广州药本君安医药科技股份有限公司 一种化合物及其制法和在制备治疗糖代谢紊乱疾病的药物中的应用
IL314677A (en) * 2022-02-16 2024-10-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Metap2 inhibitors and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) * 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
CN1191093C (zh) 1998-10-30 2005-03-02 第一制药株式会社 Dds化合物及其测定方法
AU7025600A (en) 1999-09-08 2001-04-10 School Of Pharmacy, University Of London, The Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) * 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
EP1483579A4 (en) 2002-02-15 2006-07-12 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
EP1494662B1 (en) 2002-04-11 2012-11-28 Children's Medical Center Corporation Tnp-470-hpma-methacrylic acid copolymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
CN102989009B (zh) 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
JP2008528574A (ja) * 2005-01-26 2008-07-31 チョン クン ダン ファーマシューティカル コープ. フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのMetAP−2阻害剤ポリマーソーム
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US8586019B2 (en) 2008-05-22 2013-11-19 Ramot At Tel-Aviv University Ltd. Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) * 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
US20130266578A1 (en) * 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US20130137831A1 (en) 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
AU2011336785A1 (en) * 2010-11-29 2013-06-20 Zafgen, Inc Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
KR101875988B1 (ko) * 2011-03-08 2018-07-06 자프겐 인크. 옥사스피로[2.5]옥탄 유도체 및 유사체
CA2908993C (en) 2013-04-10 2023-05-23 Syndevrx, Inc. Metap2 inhibitors and methods of treating obesity
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction

Similar Documents

Publication Publication Date Title
JP2016519106A5 (https=)
RU2012128547A (ru) Дважды ацилированные производные glp-1
CA2711834C (en) Synthetic triterpenoids and methods of use in the treatment of disease
US12129247B2 (en) Administration regime for nitrocatechols
RU2012150108A (ru) Аналоги глюкагоноподобного пептида-1 и их применение
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
JP2015526458A5 (https=)
MX2013011674A (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2010523476A5 (https=)
AU2015353492A1 (en) Fatty acid cysteamine conjugates and their use as activators of autophagy
JP2019507781A5 (https=)
JP2014518853A5 (https=)
JP2013500304A5 (https=)
JP2013540102A5 (https=)
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
JP2010529203A5 (https=)
JP2008528658A5 (https=)
JP2024540183A5 (https=)
JP2016523241A5 (https=)
JP2007527919A5 (https=)
JP2018505859A5 (https=)
JP2016128399A5 (https=)
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
EP4435001A3 (en) Crf2 receptor agonists and their use in therapy
JP2022543826A5 (https=)